Celcuity Inc (NASDAQ: CELC) saw its stock price plummet by 6.45% in intraday trading on Friday, following the release of its third-quarter 2024 earnings results. The biotechnology company reported a net loss of $29.8 million, wider than the $18.4 million loss in the same period last year.
While the company achieved a significant milestone by fully enrolling patients in the P3CA wild-type cohort for its Victoria 1 phase three clinical trial, concerns arose over the increased expenses and uncertainties surrounding the event rates in its clinical trials.
Research and development expenses soared by $10.1 million compared to the previous year, contributing to the overall financial challenges. Additionally, general and administrative expenses rose to $2.5 million, up from $1.4 million in the third quarter of 2023, reflecting higher operational costs.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。